This panel discussion, following our survey on iPSC production, of which the results can be now found in an infographic, focuses on the variations in methods and the challenges faces by scientists. It aims to assess the current state of the field by discussing the many different techniques and technology used in the production of these amazing cells, and will consider how this may evolve, as well as different applications for iPSCs in regenerative medicine.
The panellists also look at some of the wider issues that the field is facing, such as regulatory challenges, to get products to the market and clinic.
We hope this discussion is an insightful resource bringing together the latest knowledge and providing the current perspectives on iPSC production and applications, and stimulate discussion about future directions of this field.
What will you learn?
- Main techniques, technologies and materials currently in use
- The current challenges faced in producing high-quality iPSCs
- The future potential of iPSCs in therapies and other applications
- How the technology and techniques used to produce iPSCs may evolve and what new insights this could bring
Who may this interest?
- Graduate students, researchers and practitioners working in the multidisciplinary field of cell therapy and regenerative medicine.
- Individuals with an interest in iPSC production and application
- Regenerative medicine investors
- Regulators/decision-makers/policy-makers in the stem cell and cell therapy fields
Scientific Training and Support
Biological Industries USA
Lia Kent began her career with human pluripotent stem cells in 2003 at WiCell Research Institute and in the lab of Dr. James Thomson at the University of Wisconsin-Madison. For the past 14 years, she has been providing technical support and hands-on training for scientists across the world on a variety of methods, including human pluripotent stem cell culture techniques, cutting-edge reprogramming technologies, and best practices in cell culture laboratory maintenance and sterility. She currently manages technical training and scientific support at Biological Industries USA.
Business Development Consultant - Stem Cells
Thermo Fisher Scientific
Dr. Yvonne Mica completed her doctoral studies in the laboratory of Lorenz Studer at Memorial Sloan Kettering Cancer Center in New York where she established a novel system for modeling pigmentation disorders using patient iPSC-derived melanocytes. She joined Life Technologies (now a part of Thermo Fisher Scientific) as a Technical Sales Specialist in 2013 to provide guidance and support to scientists in academia and pharma interested in stem cell research. Since 2015 Yvonne has been active as a global Business Development Consultant supporting the stem cell portfolio and applications. She manages strategic alliances with key opinion leaders in the field and emerging markets and works closely with global cross-functional teams including R&D, product management, marketing and business unitsto provide market feedback and identify opportunities for the development of products and technologies that will accelerate stem cell research from the bench to the clinic.
Centre for Stem Cells & Regenerative Medicine at King’s College London
Fiona Watt obtained her DPhil from the University of Oxford, and carried out postdoctoral research at M.I.T, Cambridge, USA. She established her first lab at the Kennedy Institute of Rheumatology in London, and then moved to the London Research Institute. From 2006 to 2012 she was Deputy Director of the Cancer Research UK Cambridge Research Institute and of the Wellcome Trust Centre for Stem Cell Research, University of Cambridge. She was appointed director of the Centre for Stem Cells and Regenerative Medicine in 2013 and is also Director of the UK Regenerative Medicine Platform immunomodulation Hub.
Vice President, Automation Systems and Stem Cell Biology
The New York Stem Cell Foundation Research Institute
Daniel Paull joined NYSCF in January 2010 from University College London, where he obtained his PhD. After completing a post-doctoral fellowship at NYSCF in the lab of Dr Dieter Egli investigating somatic cell nuclear transfer as well as methods to prevent the transmission of mitochondrial diseases, Daniel went on to join the development of the NYSCF Global Stem Cell Array. Currently Daniel oversees the development of cell lines using this large-scale automated system, as well developing new and novel tools to investigate how genetics plays a role in human health and disease.
For a full list of other webinars available on RegMedNet please see here.